[go: up one dir, main page]

MX2016008369A - Composicion farmaceutica que incluye palonosetron. - Google Patents

Composicion farmaceutica que incluye palonosetron.

Info

Publication number
MX2016008369A
MX2016008369A MX2016008369A MX2016008369A MX2016008369A MX 2016008369 A MX2016008369 A MX 2016008369A MX 2016008369 A MX2016008369 A MX 2016008369A MX 2016008369 A MX2016008369 A MX 2016008369A MX 2016008369 A MX2016008369 A MX 2016008369A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
composition containing
containing palonosetron
palonosetron
pharmaceutical
Prior art date
Application number
MX2016008369A
Other languages
English (en)
Inventor
Jeong YOON Hye-
Jun Lee Sang-
Original Assignee
Samyang Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samyang Biopharmaceuticals filed Critical Samyang Biopharmaceuticals
Publication of MX2016008369A publication Critical patent/MX2016008369A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

En el presente documento se proporciona una composición farmacéutica con estabilidad mejorada que incluye palonosetrón, un método de preparación de la misma y un empaque farmacéutico que incluye la composición farmacéutica.
MX2016008369A 2013-12-23 2014-12-22 Composicion farmaceutica que incluye palonosetron. MX2016008369A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20130161890 2013-12-23
KR1020140186039A KR20150073866A (ko) 2013-12-23 2014-12-22 팔로노세트론을 함유하는 약학 조성물
PCT/KR2014/012644 WO2015099381A1 (ko) 2013-12-23 2014-12-22 팔로노세트론을 함유하는 약학 조성물

Publications (1)

Publication Number Publication Date
MX2016008369A true MX2016008369A (es) 2016-12-15

Family

ID=53787281

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008369A MX2016008369A (es) 2013-12-23 2014-12-22 Composicion farmaceutica que incluye palonosetron.

Country Status (8)

Country Link
US (1) US9877959B2 (es)
EP (1) EP3087987A4 (es)
JP (2) JP2017504615A (es)
KR (2) KR20150073866A (es)
CN (1) CN105934247A (es)
BR (1) BR112016014880A2 (es)
MX (1) MX2016008369A (es)
WO (1) WO2015099381A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105534884A (zh) * 2015-12-28 2016-05-04 山东齐都药业有限公司 一种盐酸帕洛诺司琼注射剂及其制备方法
JP6768404B2 (ja) * 2016-08-12 2020-10-14 武田テバファーマ株式会社 パロノセトロン又はその薬学的に許容される塩を含む医薬組成物
JP6705348B2 (ja) * 2016-09-23 2020-06-03 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
JP6642377B2 (ja) * 2016-10-25 2020-02-05 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
KR101802183B1 (ko) * 2016-11-16 2017-11-28 주식회사 유영제약 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물
JP6598158B2 (ja) * 2016-11-16 2019-10-30 光製薬株式会社 パロノセトロンを含有する安定な注射用液剤の製造方法
JP2019019067A (ja) * 2017-07-13 2019-02-07 ニプロ株式会社 液体製剤
CN110146601A (zh) * 2018-02-13 2019-08-20 江苏奥赛康药业有限公司 一种盐酸帕洛诺司琼注射液有关物质的检测方法
CN109875982B (zh) * 2019-04-15 2022-05-20 广东红珊瑚药业有限公司 帕洛诺司琼透皮贴剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2749094B2 (ja) 1989-01-13 1998-05-13 日本原子力研究所 イミノジ酢酸基を有する複合機能ろ過膜の製造方法
AU642178B2 (en) 1989-11-28 1993-10-14 Roche Palo Alto Llc New tricyclic compounds
JPH1135068A (ja) 1997-07-18 1999-02-09 Sekisui Chem Co Ltd エンドトキシン用容器
DE10041691A1 (de) 2000-08-24 2002-03-14 Infineon Technologies Ag Halbleiteranordnung
CN1781487A (zh) * 2000-08-30 2006-06-07 中外制药株式会社 Oct制剂
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
ATE314324T1 (de) * 2001-06-12 2006-01-15 Schott Ag Verfahren zur herstellung von borosilikatgläsern
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
MY143789A (en) 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
CN100544720C (zh) 2006-01-24 2009-09-30 江苏正大天晴药业股份有限公司 安全稳定的帕洛诺司琼组合物
KR101441459B1 (ko) 2006-10-24 2014-09-18 헬신 헬쓰케어 에스.에이. 안정성 및 생체이용률이 개선된 염산 팔로노세트론을 포함하는 연질 캡슐
JP2008280430A (ja) 2007-05-10 2008-11-20 Mitsubishi Rayon Co Ltd ヒアルロン酸の製造方法
US20100048607A1 (en) * 2008-08-25 2010-02-25 Chandrashekhar Kocherlakota Formulations comprising palonosetron
US20120018338A1 (en) * 2009-03-30 2012-01-26 Hoffman-La Roche Inc. Method for avoiding glass fogging
RU2014153544A (ru) * 2012-05-28 2016-07-20 Намикос Корпорейшн Стеклянный контейнер и способ его изготовления

Also Published As

Publication number Publication date
CN105934247A (zh) 2016-09-07
KR20160146633A (ko) 2016-12-21
EP3087987A4 (en) 2017-08-02
KR20150073866A (ko) 2015-07-01
JP2019073531A (ja) 2019-05-16
JP2017504615A (ja) 2017-02-09
EP3087987A1 (en) 2016-11-02
WO2015099381A1 (ko) 2015-07-02
US20160317524A1 (en) 2016-11-03
US9877959B2 (en) 2018-01-30
KR101920322B1 (ko) 2018-11-20
BR112016014880A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
MX2016008369A (es) Composicion farmaceutica que incluye palonosetron.
ZA201405418B (en) New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
ZA201600350B (en) Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same
ZA201405323B (en) New pyrrole compounds ,a process for their preparation and pharmaceutical compositions containing them
IN2013MU00646A (es)
MX2017001487A (es) Sofosbuvir en forma cristalina y proceso para su preparacion.
IN2014DN09798A (es)
PH12016500847A1 (en) Multi-particulate drug delivery system
HUP1300647A2 (hu) Ciklosporin A és származékainak komplexei, elõállításuk és gyógyszerészeti kompozícióik
EP3089207A4 (en) Airtight-sealing package member, production method therefor, and airtight-sealed package production method using this airtight-sealing package member
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
HK1250911A1 (zh) 微凝胶颗粒
MX2015016603A (es) Composiciones de corticosteroides.
IL245260B (en) Non-aqueous crystalline form of cabazitaxel, process for its preparation and pharmaceutical compositions thereof
WO2014128728A3 (en) Solid forms of cabazitaxel and processes for preparation thereof
EP3091013A4 (en) 1-(3-aminopropyl) substituted cyclic amine compounds, preparation method therefor, and pharmaceutical compositions and uses thereof
MX2015010417A (es) Composicion fungicida.
IN2013CH05769A (es)
IN2013CH00453A (es)
MX2012014969A (es) Composiciones farmaceuticas estables de amlodipina con telmisartan.
IN2013CH05858A (es)
IN2013CH05770A (es)
IN2013MU02771A (es)
IN2013MU03310A (es)
MX361768B (es) Proceso para preparar 5-fluoro-1-metil-3-difluorometil-1h-pirazol- 4-carbaldehido.